The Effect of Perioperative Dexmedetomidine Combined with Oxycodone Infusion during Open Pancreaticoduodenectomy: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060417

Enrollment

Unknown

Registered

2022-06-01

Start date

2022-08-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Disease

Interventions

Experimental group:Dexmedetomidine plus oxycodone hydrochloride

Control group:Normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged above 18 years; 2. Pancreatic space occupation was diagnosed; 3. Pancreaticoduodenectomy was intended to be performed under general anesthesia; 4. ASA I, II or III; 5. Able to understand and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hypertension, diabetes, cardiac insufficiency, liver and kidney insufficiency; 2. Allergic to any drug; 3. Patients dependent on opioids; 4. Changes in mental state, inability to provide adequate informed consent or refusal of the patient to participate; 5. Patients with electrocardiogram indicating block or bradycardia; 6. Patients with intraoperative blood loss greater than 1000ml or unable to undergo pancreatoduodenectomy due to tumor metastasis.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale score;Follow-up records of analgesic pump ;Dose of oxycodone hydrochloride and remifentanil during operation;Adverse reactions;	—

Secondary

Measure	Time frame
Sedation score;Score of nausea and vomiting;Patient satisfaction;	—

Countries

China

Contacts

Public ContactJiang Linghui

Zhongshan Hospital Fudan University

jiang.linghui@zs-hospital.sh.cn+86 13764350216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026